Ikena Oncology Inc (IKNA) - Total Assets
Based on the latest financial reports, Ikena Oncology Inc (IKNA) holds total assets worth $126.17 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ikena Oncology Inc - Total Assets Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's total assets have evolved over time, based on quarterly financial data. Also see Ikena Oncology Inc (IKNA) total market value for the company's overall valuation and market capitalisation.
Ikena Oncology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ikena Oncology Inc's total assets of $126.17 Million consist of 89.9% current assets and 10.1% non-current assets. Review how much debt does Ikena Oncology Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Ikena Oncology Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ikena Oncology Inc's current assets represent 89.9% of total assets in 2024, a decrease from 96.6% in 2018.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2024, down from 87.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Ikena Oncology Inc Competitors by Total Assets
Key competitors of Ikena Oncology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Ikena Oncology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.52 | 18.22 | 2.12 |
| Quick Ratio | 13.52 | 18.22 | 2.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $91.69 Million | $141.12 Million | $31.00 Million |
Ikena Oncology Inc - Advanced Valuation Insights
This section examines the relationship between Ikena Oncology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.20 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -26.3% |
| Total Assets | $141.51 Million |
| Market Capitalization | $59.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ikena Oncology Inc's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ikena Oncology Inc's assets decreased by 26.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ikena Oncology Inc (2018–2024)
The table below shows the annual total assets of Ikena Oncology Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $141.51 Million | -26.33% |
| 2023-12-31 | $192.09 Million | +11.51% |
| 2022-12-31 | $172.26 Million | -30.51% |
| 2021-12-31 | $247.88 Million | +47.19% |
| 2020-12-31 | $168.40 Million | +95.88% |
| 2019-12-31 | $85.97 Million | +315.82% |
| 2018-12-31 | $20.68 Million | -- |
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more